Target Name: USO1
NCBI ID: G8615
Other Name(s): transcytosis associated protein | USO1 variant 2 | General vesicular transport factor p115 | VDP | USO1 vesicle transport factor | TAP | P115 | OTTHUMP00000221102 | Transcytosis-associated protein | USO1 vesicle transport factor, transcript variant 2 | Transcytosis associated protein | USO1 vesicle docking protein homolog | vesicle docking protein p115 | Vesicle docking protein p115 | General vesicular transport factor p115 (isoform 2) | Vesicle-docking protein | USO1_HUMAN | Protein USO1 homolog | USO1 homolog, vesicle docking protein

USO1: The Protein of Transcytosis and Drug Target

USO1 (transcytosis associated protein) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. USO1 is a cytoplasmic protein that is expressed in most tissues and cells in the body. It plays a critical role in the process of transcytosis, which is the movement of cells from the cytoplasm to the cell surface.

Transcytosis is a vital process that is essential for the survival and proper functioning of cells. It is a process that is critical for the delivery of nutrients, oxygen, and other essential molecules to cells, as well as the removal of waste products and other cellular debris. Transcytosis is also critical for the regulation of cell growth and division, as well as the maintenance of tissue homeostasis.

Recent studies have identified USO1 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. USO1 has been shown to play a critical role in these processes, and its dysfunction has been linked to the development and progression of these diseases.

Diseases associated with USO1 dysfunction

Transcytosis is a critical process that is essential for the survival and proper functioning of cells, and its dysfunction has been linked to the development and progression of various diseases. One of the diseases associated with USO1 dysfunction is cancer.

Studies have shown that USO1 is often expressed in various types of cancer, including breast, ovarian, and prostate cancer. In addition, USO1 has been shown to play a critical role in the regulation of cell growth and division, which is a crucial factor in the development and progression of cancer.

Another disease associated with USO1 dysfunction is neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. These conditions are characterized by the progressive loss of brain cells, and USO1 has been shown to play a critical role in the regulation of neurodegeneration.

USO1 has also been shown to be involved in the development and progression of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These conditions are characterized by the immune system attacking the body's own tissues, and USO1 has been shown to play a critical role in the regulation of immune response.

Drug targeting USO1

The potential drug targeting of USO1 is based on its unique structure and its involvement in various critical processes in the body. USO1 is a cytoplasmic protein that is expressed in most tissues and cells in the body. It is composed of a unique transmembrane domain, a cytoplasmic domain, and an amino-terminal domain that is involved in protein-protein interactions.

Recent studies have shown that USO1 can be targeted by small molecules and antibodies. One of the most promising strategies for targeting USO1 is the use of small molecules that can inhibit its activity in the cytoplasm. These small molecules have been shown to be effective in treating various diseases associated with USO1 dysfunction, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another approach for targeting USO1 is the use of antibodies that are designed to recognize and selectively bind to USO1. These antibodies have been shown to be effective in treating various diseases associated with USO1 dysfunction, including cancer, neurodegenerative diseases, and autoimmune disorders.

Clinical applications

The potential clinical applications of USO1 as a drug target and biomarker are vast and varied. One of the most promising areas of study is the use of small molecules and antibodies to treat cancer.

Studies have shown that USO1 is often expressed in various types of cancer, including breast, ovarian, and prostate cancer. In addition, USO1 has been shown to play a critical role in the regulation of cell growth and division, which is a crucial factor in the development and progression of cancer.

The use of small molecules to

Protein Name: USO1 Vesicle Transport Factor

Functions: General vesicular transport factor required for intercisternal transport in the Golgi stack; it is required for transcytotic fusion and/or subsequent binding of the vesicles to the target membrane. May well act as a vesicular anchor by interacting with the target membrane and holding the vesicular and target membranes in proximity

More Common Targets

USP1 | USP1-UAF1 complex | USP10 | USP11 | USP12 | USP12-AS1 | USP12-DT | USP13 | USP14 | USP15 | USP16 | USP17L1 | USP17L10 | USP17L11 | USP17L12 | USP17L13 | USP17L14P | USP17L15 | USP17L17 | USP17L18 | USP17L2 | USP17L20 | USP17L21 | USP17L24 | USP17L25 | USP17L26 | USP17L27 | USP17L29 | USP17L3 | USP17L5 | USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25